Interventional Radiology Market: Business Challenges, Emerging Technologies & Competitive Landscape

Global Interventional Radiology Market: Scope and Methodology

This report on the global interventional radiology market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global interventional radiology market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

Read Full Report: http://www.transparencymarketresearch.com/interventional-radiology-market.html

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global Interventional Radiology market.

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market size estimations involved in-depth study of services and product features of different types of services. Additionally, market related factors such as increasing preference for technologically advanced services, product innovation, and increasing prevalence of cancer and other chronic diseases in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Interventional Radiology Market: Segmentation

Based on product type, the global interventional radiology market has been segmented into x-ray, computed tomography, magnetic resonance imaging, and ultrasound. The market has been further studied from the point of view of major application. Based on application, the market has been categorized into angiography, balloon angioplasty, embolization, biopsy, vertebroplasty-Kyphoplasty, RF ablation and others. On the basis of end user, the market has been segmented hospitals, catheterization labs, ambulatory surgical centers and others.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/interventional-radiology-market.html

Interventional Radiology Market: Geographical and Competitive Dynamics

Geographically, the global interventional radiology market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Japan, India, Saudi Arabia, UAE, Brazil, and Mexico.

The report also profiles major players in the Interventional Radiology market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Agfa-Gevaert N.V., Fujifilm Holdings Corporation, GE Healthcare, Hitachi Medical Corporation, Hologic, Inc., Medtronic plc., Philips Healthcare, Siemens Healthineers, Teleflex Incorporated, and Toshiba Medical Systems Corporation.

Cardiovascular Monitoring and Diagnostic Devices Market Responds to Impressive Progress in Medicine and Healthcare

Being the leading cause of death and witnessing a high rise in prevalence, the class of ailments that come under the purview of cardiovascular diseases is witnessing increased focus from healthcare, research, and government bodies alike. A large number of companies are venturing into the market with an innovative range of products for diagnosing and treating a variety of cardiovascular diseases. Research and development activities are being granted increasingly more funds and governments bodies are implementing various health schemes aimed at reducing the prevalence and improving awareness about cardiovascular diseases.

Transparency Market Research states that the global cardiovascular monitoring and diagnostic devices market held an opportunity of US$1.8 bn in 2015. The market is expected to expand at a 6.4% CAGR over the period between 2016 and 2024, and rise to a valuation of US$3.1 bn by 2024.

Electrocardiogram (ECG) Systems Lead on Account of Cost Effectiveness and High Efficiency

The product segment of ECG systems presently holds the largest share in the global cardiovascular monitoring and diagnostic devices market. The widespread presence and high preference for ECG systems in developed and developing regions alike are key to the segment’s leading market position. ECG systems are expected to remain the key contributor to the market’s overall revenues over 206 and 2024 as well, expanding at a 6.3% CAGR in the global market.

Read Full Report: http://www.transparencymarketresearch.com/crdiovascular-monitoring-diagnostic-devices.html

However, the segment of implantable loop recorders is expected to witness the fastest expansion, a 7.1% CAGR from 2016 to 2024. The segment is projected to benefit from the rising awareness about the use of these devices in diagnosing syncope. As several cases of the disease remain undiagnosed when other conventional diagnostic methods are used, implantable loop recorders are gaining an increased level of adoption across medical diagnostic centers globally. The valuation of the segment is expected to reach US$152.7 mn by 2024.

The segment of Holter monitors also holds immense growth promise owing to the rising prevalence of conditions such as arrhythmia and conduction block. The segment was valued at US$416.1 mn in 2015 and is expected to expand at a high single-digit CAGR from 2016 to 2024.

North America to Continue Taking Largest Share of Pie but Emerging Economies Hold More Promise

North America accounted for the largest share of the overall revenues of the global cardiovascular monitoring and diagnostic devices market in 2015. The region is expected to remain the largest market over the period between 2016 and 2024 as well. Factors such as favorable reimbursement policies, high awareness about available diagnosis and treatment methods among patients and physicians, favorable reimbursement policies, and efficient healthcare infrastructure are factors that will help North America remain at the forefront of the global market. Europe, the second largest contributor to the global cardiovascular monitoring and diagnostic devices market in 2015, will also remain a lucrative owing to large scale healthcare infrastructure development activities and rising prevalence of cardiovascular disease.

View exclusive Global strategic Business Report :http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2385

However, developing regions such as Latin America and Asia Pacific will present the most promising growth opportunities for the global cardiovascular monitoring and diagnostic devices market over the period between 2016 and 2024. The presence of vast untapped growth prospects, rising healthcare expenditure, and increasing awareness about the efficiency of available techniques and devices in effectively curing several cardiovascular conditions will remain key to the overall growth of the market.

Several research studies also state that the risk of cardiovascular diseases is substantially high in mid- and low-income economies. This substantiates the fact that a large variety of cardiovascular monitoring and diagnostic devices will be consumed in Asia Pacific and Latin America in the next few years. The market for these devices will expand at a 7.5% in Asia Pacific and a 7.3% CAGR in Latin America over the period between 2016 and 2024.

In the highly dynamic global market for cardiovascular monitoring and diagnostic devices market, the top two vendors, GE Healthcare and Philips Healthcare accounted for a more than 55% of the global market in 2015. Other key vendors in the market are Spacelabs Healthcare, St. Jude Medical, Inc., and Siemens Healthcare.

Life Science Reagents Market to Reach US$25.7 bn by 2020 owing to Rising Activities of R&D within the Field of Pharmaceuticals

Life science reagents include reagents that are used in biotechnology, bioscience and pharmaceutical industries. Since the last decade, the global life science reagents market has experienced impressive growth due to factors such as technology advancement and expansion in applications of biotechnology and biosciences in the field of healthcare and pharmaceuticals. Some other factors contributing to the growth of the life science reagents market include increasing disease prevalence and rise in their mortality rates, aging of population and increased research and development activities in the field of biosciences, biotechnology and pharmaceuticals. Based on the commercially available life science reagent products, the global life science reagents market is categorized as PCR reagent kits, cell and tissue culture reagents, flow cytometry reagents, electrophoresis reagents, chromatography reagents, in-vitro diagnostic reagents and others. In addition, the global life science reagents market is segmented on the basis of end users, namely, commercial and contract manufacturers, research and academics, clinical laboratories, and forensic laboratories.

Read Full Press Release: http://www.transparencymarketresearch.com/pressrelease/life-sciences-reagents-analytical-reagents.htm

Chromatography reagents are the most widely used reagent products thus, capturing the highest market share in the overall life science reagents market. Wide use of chromatography in almost every aspect of biotechnology-related research and product development is the prime contributing factor for the dominance of this segment. On the other hand, the market share of electrophoresis reagents is the lowest as compared to other products available in the overall life science reagents market. Technological advancement and increasing initiatives towards the expansion of scope of biotechnology and life science has led to perpetual rise in demand for life science reagents worldwide.

In terms of end users, research and academic institutions are the largest consumers of life science reagents. Technological development and corresponding rise in the number of available skilled labor in emerging economies have widened the scope for research outsourcing in the developing markets of India and Brazil. Processes such as pharmaceutical contract manufacturing and cosmetic product manufacturing constitute the largest commercial consumers of life science reagents. Due to the requirement of high capital investment to perform stability studies, formulation development and phase-I trials, several pharmaceutical companies outsource drug development operations to contract manufacturing companies to focus on their core activities of manufacturing drugs and marketing, thereby controlling the in-house budget.

The global life science reagents market is fragmented in terms of presence of a large number of multinational and local players. The mature market players such as Sigma Aldrich, Abbott Laboratories, Life Technologies, Bio-Rad and others currently dominate this market with their patent protected products and intensive growth strategies of acquiring new market entrants providing breakthrough technologies. In addition, large patent repositories of the established market players restrains the entry and growth of new players in the life science reagents market.

Get a Free Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1162

Geographically, North America dominates the global life science reagents market and is followed by Europe. Asia-Pacific is expected to show the highest growth rate owing to factors such as increasing research and development activities, rise in the number of government aids, business clusters and trade conglomerates to strengthen biotechnology industry in the respective national markets and rise in the availability of skilled manpower at cheaper cost, thereby increasing the scope for outsourcing of biotech projects. New trend of outsourcing research activities in Asia-Pacific is one of the major driving forces for the growth of the life science reagents market in this region. Countries such as Brazil, Mexico and Argentina in the Rest of the World (RoW) region are adopting strategies such as formation of biotechnology clusters and attracting foreign investments to boost the domestic biotechnology industry. However, stringent regulatory rules restrain the entry of new products in the market and thus, restrict the growth of life science reagents market in these countries.

Global Regenerative Medicine Market to Reach US$6.5 bn by 2019, Propelled by Increasing Demand for Tissue Engineering and Stem Cell Therapy

Regenerative medicine, according to the US National Institutes of Health (NIH), is the process of developing functional tissues for the repair and/or replacement of damaged organs or tissues. Having lost function due to disease, congenital defects, and age, these tissues or organs are regenerated to establish and restore normal function.

Regenerative medicine is used in a wide range of applications including neurology, musculoskeletal, cardiovascular, and orthopedic. Earlier this month, a study showed that a new regenerative medicine appears to relieve eye pain, light sensitivity, and burning, and stimulate faster tissue repair following eye surgery. Findings by a team of researchers in Turkey suggest that this new compound can be beneficial for all those patients who undergo refractive surgery and corneal implants.

Read Full Report: http://www.transparencymarketresearch.com/regenerative-medicines-market.html

Demand for Tissue Engineering to Rise amid High Cost of Biomaterials

Regenerative medicine is an emerging branch of medical science and is being extensively used to treat cardiovascular disease, musculoskeletal disease, and orthopedic disorders. The growing prevalence of bone and joint disorders and the rise in orthopedic surgeries have fuelled the demand for regenerative medicines. Furthermore, technological innovations in stem cell therapy, biomaterials, and tissue engineering have supported the growth of the global regenerative medicines market. However, regulatory constraints pose a threat to the development of regenerative medicines. “Ethical issues related to allogeneic bone grafts and stem cell therapy, and post implantation infections are impeding the growth of the overall market,” the analyst states.

Technology has played a pivotal part in the success of regenerative medicines. Favorable reimbursement policies had augmented the demand for biomaterials in 2012. However, tissue engineering is being increasingly preferred over biomaterials. In fact, during the period between 2013 and 2019, tissue engineering is anticipated to expand at the fastest pace. “The high cost of biomaterials has led to their decreased adoption among patients,” the analyst mentions.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=419

The global regenerative medicine market is anticipated to expand at a CAGR of 12.8% during the period between 2013 and 2019. The overall market stood at a valuation of US$2.6 bn in 2012 and is projected to be worth US$6.5 bn by 2019.

Global Regenerative Medicine Market: Geographical Segmentation

Regionally, North America is the key contributor to the global regenerative medicine market due to the presence of several leading market players in the region, which has led to the latest advances in the field becoming easily available to patients. The well-funded R&D environment in the U.S. is also a key driver for the North America bone and joint regenerative medicine market, which is likely to remain a dominant regional market for regenerative medicine in the coming years.

Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=419

Asia Pacific is likely to emerge as a leading regional market for bone and joint regenerative medicine in the coming years. The increasing patient pool of bone and joint conditions and the steady rise in healthcare expenditure in Asia Pacific are vital in ensuring sustained growth of the Asia Pacific regenerative medicine market in the coming years. Many key multinational players in the regenerative medicine market have identified Asia Pacific as a high-potential market for the future and have accordingly taken steps to expand their presence in the region.

Key players examined in the report include Smith & Nephew plc, Anika Therapeutics Inc., DePuy Synthes Inc., Baxter International Inc., Stryker Corporation, Medtronic Inc., Arthrex Inc., Zimmer Holdings Inc., and CONMED Corporation.

Non-Hodgkins Lymphoma (NHL) Therapeutics Market rises with rising prevalence of Non-Hodgkin’s lymphomas (NHL)

Lymphoma is one of the most hazardous and life threatening type of cancer, related to lymphocytes, an important type of white blood cells. Non-Hodgkin’s lymphomas (NHL) is a distinct group of blood cancer, which includes large variety of lymphomas, excluding Hodgkin’s lymphomas. Non-Hodgkin’s lymphoma (NHL) varies in their severity, from mild to fatal. According to a new classification of lymphomas published by WHO in 2008, the lymphomas are segmented into four different groups, instead of segregating as Hodgkin’s and Non-Hodgkin’s lymphomas. The list comprises of around 80 various types of lymphomas.

The major causes of Non-Hodgkin’s lymphomas (NHL) include chemical interaction, such as, interaction with diphenylhydantoin, polychlorinated biphenyls and other toxic compounds, autoimmune disorders, such as, rheumatoid arthritis, celiac sprue, Sjogren’s syndrome and others, medication and radiation therapy, infections, such as, H. pylori infection, HIV infection, hepatitis C viral infection, human T-cell leukemia virus, Epstein-Barr virus and others, genetic disorders such as ataxia telangiectasis syndrome, Klienfelter’s syndrome and others. Major symptoms of the disease includes night sweats, itchy skin, frequent high fever, breath shortness, loss of appetite and weight and painless sweating of lymph nodes present on various locations in the body.

The market of Non-Hodgkin’s lymphomas (NHL) is segmented on the basis of phase of the disease (severity), such as, phase I, II, III, and IV. Further, the market is segmented on the basis of types of Non-Hodgkin’s lymphomas (NHL), such as, AIDS-related lymphomas, Mantel Cell lymphoma, cutaneous T-cell lymphoma, blastic NK-cell lymphoma, T-cell leukemia, Burkitt’s lymphoma, follicular lymphoma, Waldenstrom’s Macroglobulinemia and many others. Furthermore, the market is segmented on the basis of therapeutic agents, such as, chemotherapy, stem cell therapy, radiations, novel targeted target therapy and other. A large number of therapeutic agents are used to treat Non-Hodgkin’s lymphomas (NHL), such as methotrexate, bortezomib, cyclophosphamide, bleomycin, chlorambucil, liposomal cytarabine, nelarabine, doxorubicin hydrochloride and many others.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2668

Moreover, the market is segmented on the basis of geography, such as, North America, Europe, Asia-Pacific and Rest of the World (RoW). At present, North America and Europe are the most prominent markets, owing to extensive research practices. However, Asia-Pacific and some countries in RoW region are expected to show lucrative growth in the upcoming period, owing to enhanced awareness about cancer and growing research practices.

The market of Non-Hodgkin’s lymphomas (NHL) is driven by many promoting forces, such as, rising prevalence of Non-Hodgkin’s lymphomas (NHL) and other types of cancer, extensive R&D practices, rising concern of the population towards effects of Non-Hodgkin’s lymphomas (NHL) and rise in medical and healthcare expenditure and infrastructure. Rising prevalence of Non-Hodgkin’s lymphomas (NHL) is one of the most important market drivers. According to American Cancer Society’s recent estimations, around 71,000 new patients are diagnosed with Non-Hodgkin’s lymphomas (NHL) in 2014, and the number of deaths is expected to be around 19,000 in 2014.

Request For Custom Research: http://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=2668

Furthermore, extensive R&D practices is another important market growth factor of this market. As of now, large number of pharmaceutical companies engaged in R&D practices in order to develop innovative formulations. For instance, Rituximab SC (Roche, Inc.) is under phase III studies. On the contrary, high cost of R&D and treatment and chronic side effects are the biggest hurdles in the market growth.

Some of the key players operating in Non-Hodgkin’s Lymphoma (NHL) Therapeutics market and engaged in the development of new formulations for Non-Hodgkin’s lymphomas (NHL) include F. Hoffmann LA Roche, Inc., Amgen, Inc. ,Eli Lilly and Company, Novartis International AG, Bayer AG, Pharmacyclics, Inc., Nordic Nanovector A/S, AbbVie, Inc. and many others.

Restriction Endonucleases Products Market - Global Industry Analysis, Trends and Forecast 2015 – 2023

Restriction enzymes or restriction endonucleases (RE) are the enzymes that are found in the bacteria and are harvested from them for their use in research and commercial aspects. These enzymes cut the deoxyribonucleotide (DNA) at specific nucleotide sequences and the biological function of these enzymes is to protect cells from foreign DNA . Nomeclature for these enzymes is based on the first letter of the genus followed by first two letters of the species and name of the bacteria of origin. These enzymes find applications in various research activities involving molecular biology techniques.

For instance, these enzymes are used as key reagents in processes such as restriction fragment length polymorphism (RFLP), genomic mapping, several recombinant procedures and DNA sequencing. There are four classes of restriction endonucleases namely types I, II, III and IV of which class II enzymes are the most popular and more useful as compared to others. The reason being the specific determination of the DNA sequences and generate termini with 5’ phosphate and 3’ hydroxyl groups and are capable of recognizing non-palindromic sequences. There has been continuous evolution of the new prototype activities that render continuous updates about new recognition sites along with the commercial availability. REBASE is such one database that provides monthly updates about the above mentioned factors.

Till date more than 10,000 bacteria are screened for the presence of restriction enzymes and currently there are more than 2,500 restriction enzymes have been discovered along with over 250 distinct specificities in sequences. The microorganisms that produce RE also produce DNA methyltransferases and this feature protects their own DNA from cleavage.

These enzymes are used in conventional cloning, deciphering epigenetic modifications, construction of DNA libraries and in vivo gene editing. The market for restriction endonucleases can be segmented by various types that are available commercially and the respective application areas. Companies such as New England Biolabs, Inc. and Thermo Fisher Scientific engage in development and marketing of various types of restriction enzymes (A-Z). For instance, New England Biolabs, Inc. offers restriction enzymes in variable sizes such as 500 and 2,500 units. These units are priced at USD 57.00 for one unit. In addition, Thermo Fisher Scientific also offers these by FastDigest (176) brand and Conventional enzymes.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4175

Factors such as regulatory policies and product approvals govern the market growth. Furthermore, it can be classifies by the applications and end users. Pharmaceutical and biotechnology companies along with academic research institutes utilize these REs in various activities. Geographically, North America and Europe are the highest revenue generators in this market owing to increasing research and development activities followed by the presence of manufacturers in these regions. On the other hand Asia Pacific and Rest of the World (RoW) regions present lucrative opportunities for the growth of this market due to increasing research projects funding by the respective governments followed by increasing commercial production of these enzymes.

There is a tremendous growth potential in acceptance of these enzymes owing to increasing implementation of molecular biology techniques and processes followed by increasing research and development activities making use of these enzymes. On the other hand, factors such as high cost of downstream activities coupled with variable reliability and accuracy of these enzymes are some factors that might restrain the market growth. Agilent Technologies, Inc., Genetix Biotech Asia Pvt. Ltd., New England Biolabs, Inc., ThermoFisher Scientific, Inc., and Promega Corporation are some of the key market players operating in this market.

Europe Ambulatory Surgical and Emergency Center Services Market Propelled by Increasing Geriatric Population, Poised to Reach US$42.8 bn by 2020

With few companies presently operating and a large number of vendors expected to be enter in the next few years, the Europe ambulatory surgical and emergency center services market features a moderate level of competitive rivalry, reports a recent TMR report. The vast growth opportunities in the market can be understood from the fact that nearly 98% cataract surgeries and nearly 63% hernia repair surgeries are undertaken in ambulatory surgical units in the U.K. presently.

Only a few companies in the market, such as Community Health Systems, Inc., Healthway Medical Group, and Medical Facilities Corporation, have operations across more than four specialty segments that come under the purview of the market. As a result, these three companies, with operations across a larger number of these specialty segments, including ophthalmology, pain management, gastrointestinal ailments, orthopedic, and dermatology, presently command leading positions in the market. Other key vendors in the market are AmSurg Corporation, Eifelhoehen-Klinik AG, NovaMed, Inc., and Symbion, Inc.

Long Waiting Periods for Specialist Appointments and Reduced Treatment Costs Increase Preference to Single-day Surgeries

Long waiting periods for availing specialist appointments and undergoing complex surgeries are a key factor compelling patients to migrate from hospitals to day care centers or free standing units. Studies have indicated that across European countries such as the U.K., France, Norway, and Sweden, the issue of dearth of timely access to medical services is a key factor driving the demand for ambulatory surgical and emergency center services, which promise timely execution of surgeries. The vast reduction in costs of overall treatment possible with opting day surgery options is also a key factor driving the increased demand for ambulatory surgical centers in Europe.

Along with these factors, the vast technological advancements in the field of surgery, which have enabled the formation of smaller and fewer wound sites and faster recovery of patients, has also helped increase the number of surgeries that can be undertaken in outpatient settings. The vast rise in Europe’s geriatric population and increased life expectancy, leading to an increased number of patients with chronic health conditions, have also significantly boosted the requirement for ambulatory surgical and emergency center services in Europe.

Lack of Adequate Facilities and Reluctance to Day Surgeries to Hinder Market Growth

The lack of adequate facilities for ambulatory surgeries across a vast number of healthcare facilities in Europe is a key factor restraining the growth prospects of the Europe ambulatory surgical and emergency center services market. The presence of a large number of conventional hospital beds in countries like Austria compel patients to opt for conventional surgical procedures.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3676

Along with this, the reluctance shown by some people for day surgeries, owing to the belief that day surgeries could be unsafe and not very effective, is also a chief factor limiting the overall growth prospects of the Europe ambulatory surgical and emergency center services market. Similarly, reluctance by primary care teams to adopt day surgeries, owing to the belief that the transition would result in an increase in their workloads, is also restraining the market’s growth to a certain extent.

Orthopedic Surgeries to Take the Lead

Transparency Market Research states that the Europe ambulatory surgical and emergency center services market, which had a valuation of US$23.08 bn in 2015 in terms of revenue, is expected to rise to US$42.81 bn by 2020. The segment of orthopedic surgeries is presently the leading contributor to the market’s overall revenues, having a valuation of US$11.39 bn in 2015. It is also expected to a key contributor to the market’s revenue over the forecasting horizon. In terms of geography, the U.K. emerged as the top revenue generator in the overall market, with a revenue contribution of US$6.10 bn in 2015.

This review is based on a recent market research report published by Transparency Market Research, titled “Europe Ambulatory Surgical & Emergency Center Services Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020.”

Limitations Associated With Use of Allografts and Autografts to Bring Orthobiologics at Forefront

Orthobiology is a branch of science that develops bone and tissue replacement materials for fasthealing and quick recovery of injured muscles, broken bones, ligaments and tendons. Orthobiologics is considered as a highly lucrative market owing to significant growth opportunities. One of the major driver for the growth of this industry is certain limitations that are associated with autografts and allografts. Although, autografts are considered as gold standard for orthopedic procedures but the usage of autograft involves donor site morbidity and an additional surgery. While, the major concerns associated with allografts is risk of disease transmission along with the decline in theiravailability. Therefore, in order to overcome these drawbacks of the autografts and allografts, bone graft substitutes are being preferred for use in orthopaedic surgery.

According to the American Academy of Orthopedic Surgeons (AAOS), approximately 465,000 spinal surgeries were performed in the U.S in 2011. Of all the spinal fusion surgeries performed, 46% were for lumbar fusion, 42% were for cervical fusion and the remaining 13% were for thoracic or multi-level fusion procedures. This rise in number of spinal fusion surgeries has created the demand for bone graft substitutes and has consequently boosted the overall growth of this industry. In addition, rise in the incidence of arthritis, increase in geriatric population and increase in obesity rate has triggered the growth of this market. Technological advancements, growing demand for minimally invasive procedures and rising patient awareness are the other factors that has considerably augmented the growth of this market. The global orthobiologics market was valued at USD 3,754.6 million in 2012 and is expected to grow at a CAGR of 5.9%from 2013 to 2019 to reach at an estimated value of USD 5,519.9 million in 2019.

At present, viscosupplementation accounts for the largest share of the orthobiologics market. The growth in this market is attributed to growing popularity of knee treatments and its ability to act as an effective pain killer as compared to NSAIDS and others. This market is followed by bone morphogenetic proteins (BMPs) which is characterized by its ability to provide faster recovery, lesser pain and ability to stimulate patients own cells for regeneration. However, the market is expected to show a negative growth rateduring the forecast period due to decline in the sales of “INFUSE” a Medtronic product. Severe side effects associated with INFUSE due to its heavy off label usage led to recall of this product by the U.S FDA. Synthetic bone substitutes and stem cell based products are expected to witness a significant growth during the forecast period. The growth of these segments is witnessed due to reduced cost, quick recovery and eliminated risk of disease transmission.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1747

Geographically, North America and Europe dominates the orthobiologics market. The dominance in these region is witnessed due to rise in incidence of arthritis and higher obesity rates that has surged the demand for minimally invasive procedures such as bone grafting and growth factor treatment. These treatments offer enhanced well-being and durability, with minimal side effects while eliminating the need for repeated hospital visits. However, the Asia-Pacific region is expected to show highest growth rate during the forecast period. The demand for orthobiologics in this region is witnessed due to increase in number of orthopedic disease due to change in lifestyle, change in diet which all lead to increasing obesity rate and consequently leads to arthritis and other bone disorders. Moreover, rise in geriatric population and increase in sports related injuries are other factors likely to drive the growth of orthobiologics in this region.

The major players engaged in the orthobiologics market include Medtronic, Inc., DePuySynthes, Wright Medical Technology, Inc., Stryker Corporation, Orthofix, Inc., NuVasive, Inc., and other significant players.

Safety Syringes Market : Recent Industry Trends and Projected Industry Size by 2013 – 2019

The competitive landscape of the global safety syringes market is highly consolidated with the presence of a few key players, observes Transparency Market Research (TMR). These are Becton, Dickinson & Company, Smiths Medical, Retractable Technologies Inc., Revolutions Medical Corporation, Covidien plc, Terumo Corporation, and Unilife Corporation.

“Acquisitions and alliances are the focus of key players in the market to supplement internal growth with the objective to boost revenue growth”, says the lead author of the study. A case in point is, in December 2012, Becton, Dickinson & Company acquired Safety Syringes Inc. This led the former to strengthen its market position while also expanding its product portfolio.

An increasing number of investments in high-impact areas is another key growth strategy adopted by key players in the global safety syringes market. Companies are strategizing to invest heavily in sales and marketing at the global level. Top players in this market are also focused on research and development to develop newer safety syringes and needle devices with automated retraction.

Government Mandates for Safety Mechanism of Syringes Favor Market Growth

“The increasing number of needlestick injuries is the major factor driving the global safety syringes market”, says lead analyst of the study. According to the World Health Report 2002 analyzed by the World Health Organization, of the 35 million healthcare workers worldwide, almost 2 million undergo percutaneous exposure to infections every year. An increasing number of blood borne diseases such as hepatitis C, diphtheria, herpes, tuberculosis, hepatitis B, typhus, and malaria.

The continuous growth in the injectable drugs market is another major factor driving this market. This is because injectable drugs market is likely to display demand for drug delivery devices for drug administration that has been designed keeping up with safety requisites. Governmental legislations that require manufacturers to develop syringes equipped with safety mechanisms is also driving the global safety syringes market.

Price Factor Leads to Limited Use in Developing Nations

“The high cost associated with safety syringes is one of the major factors holding back the growth of the safety syringes market,” says the author of the study. According to the International Council of Nurses (ICN), a retractable safety syringe costs more than two times than a normal syringe. This factor is more prominent in developing nations such as China, India, and Brazil where healthcare providers tend to avoid spending money on safety syringes. Healthcare providers in these regions believe that needlestick injuries can be prevented by training healthcare workers to use normal syringes safely.

The growth of the safety syringes market is also impeded due to the rising popularity of non-invasive drug delivery techniques and continued development in alternate drug delivery technology that may be used in place of injectable drug delivery.

Get Free PDF Brochure for more Professional and Technical industry insights: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2079

The global safety syringes market will be valued at US$6.5 bn by 2019.

Non-retractable safety syringes account for the larger share of the market on the basis of product. In 2012, non-retractable safety syringes held the larger share of the market both in terms of volume and value.

North America is the largest market for safety syringes. In 2012, North America dominated the global market for safety syringes due to an early adoption of advanced equipment and advanced technology for rendering healthcare services.

The information presented in this review is based on the report, “Safety Syringes Market - Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast, 2013 - 2019.”

Government Support Crucial for Widespread Adoption of Stem Cell Therapy

Stem cells are a type of human cells that give rise to the various types of cells found in the human body. Stem cells hold the potential to evolve into various types of human tissue, which has led to a growing acknowledgement of the obvious medical potential of this property. Stem cell therapy is becoming increasingly common in the treatment of various diseases and the increasing research in the field is expected to further drive the medical applications of stem cells in the coming years.

According to Transparency Market Research, government support is expected to be crucial in the global stem cells market’s expected rise from a 2013 valuation of US$26.3 bn to a valuation of US$119.5 bn by 2018. The market is expected to exhibit a robust 24.2% CAGR between 2012 and 2018.

Download Complete Healthcare Analytical Brochure:  http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

What are the major advances in the field of stem cells and their medical application?

In July 2016, a joint Dutch-Canadian research effort succeeded in discovering a viable method of increasing the amount of stem cells obtained from cord blood. Cord blood, which is blood from the placenta, contains a relatively small amount of stem cells per unit. The method formulated in the research allows researchers to increase the amount of stem cells obtained from cord blood, making this is a crucial advancement in the field of stem cell therapy.

The team discovered that mirR-125a, a microRNA, is responsible for the property of stem cells to self-renew. This genetic ‘switch’ remains activated in stem cells but is inactivated in the progenitor cells formed from the division of stem cells. Success in activating this switch would result in self-sustaining production of stem cells, which will be a major boost for the global stem cell therapy market.

In April this year, a research team at McMaster University in Hamilton, Ontario, discovered the protein responsible for the growth and development of blood stem cells. The Musashi-2 protein could be the key to helping thousands of patients of various blood disorders, as understanding the ambit of the protein could allow researchers to increase the number of viable stem cells available for therapeutic use.

What are some of the major drivers for the stem cells market?

The key driver for the global stem cells market is the increasing government support across the world. As widespread incorporation of stem cell therapy allows a nation to significantly improve the overall healthcare scenario, countries in North America and Western Europe have provided solid support to stem cell research. The acceptance of stem cell therapy in emerging regions is still lagging behind due to the lack of advanced medical infrastructure to adopt stem cell therapy, but the steady improvement of the healthcare sector in countries such as India and China is likely to be a major growth driver for the global stem cells market.

The increasing prevalence of neurodegenerative disorders is another major driver for the global demand for stem cells. Neural tissue can’t be regenerated or replaced as easily as structural tissues, and the ability of stem cells to develop into human cells provides the perfect avenue for treatment of neurodegenerative conditions.

Life Science Reagents Market To See Good Times Ahead

Life science reagents include reagents that are used in biotechnology, bioscience and pharmaceutical industries. Since the last decade, the global life science reagents market has experienced impressive growth due to factors such as technology advancement and expansion in applications of biotechnology and biosciences in the field of healthcare and pharmaceuticals. Some other factors contributing to the growth of the life science reagents market include increasing disease prevalence and rise in their mortality rates, aging of population and increased research and development activities in the field of biosciences, biotechnology and pharmaceuticals. Based on the commercially available life science reagent products, the global life science reagents market is categorized as PCR reagent kits, cell and tissue culture reagents, flow cytometry reagents, electrophoresis reagents, chromatography reagents, in-vitro diagnostic reagents and others. In addition, the global life science reagents market is segmented on the basis of end users, namely, commercial and contract manufacturers, research and academics, clinical laboratories, and forensic laboratories.

Chromatography reagents are the most widely used reagent products thus, capturing the highest market share in the overall life science reagents market. Wide use of chromatography in almost every aspect of biotechnology-related research and product development is the prime contributing factor for the dominance of this segment. On the other hand, the market share of electrophoresis reagents is the lowest as compared to other products available in the overall life science reagents market. Technological advancement and increasing initiatives towards the expansion of scope of biotechnology and life science has led to perpetual rise in demand for life science reagents worldwide.

In terms of end users, research and academic institutions are the largest consumers of life science reagents. Technological development and corresponding rise in the number of available skilled labor in emerging economies have widened the scope for research outsourcing in the developing markets of India and Brazil. Processes such as pharmaceutical contract manufacturing and cosmetic product manufacturing constitute the largest commercial consumers of life science reagents. Due to the requirement of high capital investment to perform stability studies, formulation development and phase-I trials, several pharmaceutical companies outsource drug development operations to contract manufacturing companies to focus on their core activities of manufacturing drugs and marketing, thereby controlling the in-house budget.

The global life science reagents market is fragmented in terms of presence of a large number of multinational and local players. The mature market players such as Sigma Aldrich, Abbott Laboratories, Life Technologies, Bio-Rad and others currently dominate this market with their patent protected products and intensive growth strategies of acquiring new market entrants providing breakthrough technologies. In addition, large patent repositories of the established market players restrains the entry and growth of new players in the life science reagents market.

Get a Free Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1162

Geographically, North America dominates the global life science reagents market and is followed by Europe. Asia-Pacific is expected to show the highest growth rate owing to factors such as increasing research and development activities, rise in the number of government aids, business clusters and trade conglomerates to strengthen biotechnology industry in the respective national markets and rise in the availability of skilled manpower at cheaper cost, thereby increasing the scope for outsourcing of biotech projects. New trend of outsourcing research activities in Asia-Pacific is one of the major driving forces for the growth of the life science reagents market in this region. Countries such as Brazil, Mexico and Argentina in the Rest of the World (RoW) region are adopting strategies such as formation of biotechnology clusters and attracting foreign investments to boost the domestic biotechnology industry. However, stringent regulatory rules restrain the entry of new products in the market and thus, restrict the growth of life science reagents market in these countries.

Laboratory Information System Market - Worldwide Market Shares, Strategies, and Forecasts 2013 to 2019

A laboratory information system is a complex information system designed for data and information management related to industrial and medical-related laboratories including clinical and analytical laboratories. Laboratory information system allows users to obtain, store, manage, retrieve and record laboratory data. Laboratory information system provides information that helps in the diagnosis, prevention, management and treatment of disease, as well as being an indicator for individual and population health. There is no standard laboratory information system designed due to the fact that client laboratories are highly diverse and have different requirements. Therefore, a laboratory information system is developed, customized and configured according to the needs of a laboratory. Globally, improvement in healthcare services is playing a major role in increasing the demand of laboratory information system. As a result, this market is expected to grow at a CAGR of about 7.7% during 2013 – 2019.

Some of the key driving factors for the laboratory information systems market are increasing need for integrated healthcare information systems, rising government initiatives and rising investments by healthcare IT players. Also, improvement in healthcare services in different parts of the world is increasing the global laboratory information systems market. However, the market faces some restraints such as lack of experienced professionals, high maintenance and service expenses and interoperability issues. Increasing use of mobile phones and companies focusing on new product launches are some of the major trends witnessed in the laboratory information systems market.

North America has the largest laboratory information systems market. Rising cases of fatal diseases and their diagnostic and treatment needs are some of the major factors driving the demand for laboratory information systems in the region. Also, its public funded structure is acting as a significant driver for the North American market for laboratory information systems. In addition to increasing disease incidences, government initiatives to promote the use of laboratory information systems have resulted in Europe becoming the fastest growing laboratory information systems market. At the country level, some of the fastest growing markets for laboratory information systems market include Japan, Germany, U.S. and U.K.. Emerging markets which hold huge potential and increasing demand for powerful IT systems in diagnostic and medical laboratories are some of the major opportunities for the laboratory information systems market.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1482

Clinical diagnostics laboratory information system has the largest market share on the basis of its applications and is expected to grow at a CAGR of about 8.9% during 2013 – 2019. On the basis of its mode of delivery, the market can be classified into web based technology, on-premise technology and cloud based technology market for laboratory information systems.

McKesson Corporation is the leading player in the laboratory information systems market. Other major players of laboratory information systems market include Merge Healthcare Incorporated, Cerner Corporation and others.

Global Cord Blood Banking Services Market Hampered by Blood Shortage and Restrictive Usage; Market to Reach US$15.23 bn by 2019

Stem cells are capable of producing all the three types of blood cells produced in human body i.e. red blood cells, platelets and white blood cells. Researchers have discovered that stem cells can be used for the treatment of 80 different diseases including thalassemia, sickle cell anemia, leukemia diabetes and cardiac diseases. The major sources for stem cell banking are storing of peripheral blood and bone marrow, umbilical cord blood (UCB) is by far considered as the largest component for hematopoietic stem cells. Donated cord blood has become one of the most reliable sources for stem cells over the last decade and is thus considered as a valuable biological resource. The chances of cord blood sample matching with the patients that is closely in relation to the baby whose sample is to be used are 39% more than the sample obtained from the public banks. Cord blood banking services is a promising and a fast growing segment in the field of next generation stem cell therapy and national cord blood registries are changing perception and look of the industry.

Cord blood can be stored in either of the two ways, banking in private cord blood banks or donating in public cord blood banks. Private cord blood banks collect and store cord blood for the use of baby and close family members only. Collection and storage of the cord blood is charged to the parents of the baby. And secondly the cord blood can be donated to a public bank where the cord blood unit is stored and is publically available for the suitable match. All the charges of storage and maintenance of the cord blood unit obtained from public bank are taken from the patient or patient’s family for whom the unit is going to utilize in transplantation process. Though globally the number of private cord blood banks are more as compared to public banks, number of units stored in public banks are more than units of cord blood banks stored in private banks globally.

The amount of stem cells required for the transplantation process vary depending on person’s weight and age. The major disadvantage of cord blood storing in private cord blood bank is that the single unit of the cord blood contains insufficient amount of stem cells and becomes difficult to treat adults using stem cell transplant. On the other hand, cord blood units stored in public banks is available to any patient matching with the blood unit sample stored in public banks globally. And hence multiple units can be utilized for single patient to meet the requirement of the stem cells in transplantation procedure.

Taking inability of the privately stored cord blood units to meet the requirement of the amount of stem cell into consideration healthcare professionals are focusing on enhancing cord blood inventory in public banks so that demand for the cord blood units can be matched. Gynecologists, pediatricians and obstetricians recommend to store cord blood in private banks only if the family has history of the disease that can be treated using stem cells.

Downlaod Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1741

Geographically North America is dominating the global cord blood banking services market followed by Europe. Governments taking initiative to regulate the cord blood banking industry in the country and implementation of hybrid model to reduce the attrition between private cord blood banking and public cord blood banks is driving the growth of cord blood banking services market. Asia-Pacific is lucrative market owing to increased cord blood banking in countries like China and India. Contribution of Asian countries in banking cord blood is expected to increase further as medical tourism industry is booming in this region. Growing awareness about cord blood banking and treatments that can cure blood borne diseases using stem cells in cord blood is increasing. Countries like France, Italy and UAE have banned private banking of the cord blood. Governments of these countries are actively participating in establishing nationwide public banks to enhance the inventory of the cord blood units.

Global Regenerative Medicine Market to Reach US$6.5 bn by 2019, Propelled by Increasing Demand for Tissue Engineering and Stem Cell Therapy

Regenerative medicine is considered as an emerging field of medical science that aims to regenerate, repair or replace damaged tissue and organs. U.S. National Institute of Health stated that regenerative medicine is the process of creating functional tissue to repair and replace tissue or organ which has lost their function due to damage, congenital defects, disease and age. Regenerative medicine has wide areas of application such as cardiovascular, neurology, orthopedic and musculoskeletal diseases and disorders. Technological advancement in tissue engineering and stem cell therapy is expected to drive the global market for regenerative medicine (bone and joint). Moreover, growing prevalence of bone and joint disorder has also accounted for the market growth of the global regenerative medicine (bone and joint). However, factors such as stringent regulatory compliance, ethical issues pertaining to stem cell therapy and post implantation rejection are expected to hinder the global market growth during the forecast period. The global regenerative medicine (bone and joint) market was valued at USD 2,589.5 million in 2012 and is expected to grow at a CAGR of 12.8% from 2013 to 2019, to reach an estimated value of USD 6,473.4 million by 2019.

The global market for regenerative medicine is segmented based on technology as stem cell therapy, biomaterials and tissue engineering. In 2012, biomaterials segment accounted for the largest market share in the global regenerative medicine (bone and joint) market owing to favorable reimbursement policies and strong demand of biomaterials in the global market. Moreover, tissue engineering is expected to grow at the highest CAGR during the forecast period.

In addition, the global market for regenerative medicine (bone and joint) is segmented based on application as bone graft substitute, osteoarticular diseases, allogeneic bones, autogenic bones and others. In 2012, bone graft substitute segment accounted for the largest market share in the global regenerative medicine bone and joint application market owing to growing demand of bone graft substitute in orthopaedic surgeries. Autogenic bone application segment is expected to grow at the highest CAGR during the forecast period 2013 to 2019.

North America was the largest market for regenerative medicine bone and joint application in 2012, accounting for largest market share of the total regenerative medicine (bone and joint) market. The regenerative medicine market in North America witnessed significant growth due to increasing demand of bone and joint reconstructive surgeries. Moreover, favorable government initiatives have also supported the growth of the regenerative medicine bone and joint application market in this region. European market was the second largest of the global market in 2012. Rising geriatric population in European Union is one of the major market drivers in this region as the geriatric group is more prone to suffer from arthritis. Moreover, extensive support and funding provided by European government for regenerative medicine would further accentuate the market growth in this region.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=419

Asia-Pacific was observed to be a promising market for regenerative medicine bone and joint application during the study period owing to the demand of bone graft substitute in this region. This region is considered as an emerging market and is estimated to grow at the highest CAGR from 2013 to 2019. Manufacturer of regenerative medicine bone and joint products are expanding their operation in Asian countries (India, China, Japan and South Korea) as these economies hold immense potential for regenerative medicine bone and joint application. For instance, in May 2013, Smith & Nephew acquired Sushrut Surgical Pvt. Ltd. an Indian medical technology company. Sushrut Surgicals product portfolio includes trauma implants and instruments, spine and limb salvage products. This acquisition would expand and enhance the product offerings of Smith & Nephew and would also assist in capturing lucrative market share in Asia-Pacific region. In terms of key players the global regenerative medicine bone and joint application market is highly fragmented that comprises of DePuy Synthes, Inc. (HEALOS Bone Graft), Medtronic, Inc. (INFUSE Bone Graft), Stryker Corporation (Vitoss Bone Graft Substitute) and Zimmer Holdings, Inc (CopiOs Bone Void Filler).

Global Stem Cells Market to Reach US$119.5 bn by 2018, Rising Awareness about Therapeutic Benefits Boosts Popularity

Transparency Market Research, in a report titled “Stem Cells Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018”, states that the global stem cells market is projected to witness remarkable growth from 2012 to 2018, fueled by increasing government support, unmet medical needs, rising stem cell banking services, and growing medical tourism. Driven by these factors, the global stem cells market is anticipated to expand at a 24.20% CAGR during the forecast period, rising from a value of US$26.2 bn in 2013 to US$119.5 bn by 2018.

Rise in disposable income in emerging economies, the increasing prevalence of neurodegenerative disorders, development of the contract research industry, and replacement of animal tissue in drug discovery are also anticipated to contribute towards the overall growth of the stem cells market.By product, the stem cells market is categorized into adult stem cells, induced pluripotent stem cells, very small embryonic-like stem cells, human embryonic stem cells, and rat neural stem cells. Adult stem cells, which dominated the overall market in 2011, include mesenchymal stem cells, dental stem cells, neuronal stem cells, hematopoietic stem cells, and umbilical cord stem cells.

On the basis of technology, the stem cells market is segmented into stem cell acquisition, production, cryopreservation, and expansion and sub-culture. Stem cell acquisition is the largest as well as the most rapidly developing technological segment and includes bone marrow harvesting, umbilical cord blood, and apheresis. The segment of stem cell production includes cloning, isolation, in-vitro fertilization, and cell culture.

On the basis of application, the stem cells market is bifurcated into regenerative medicine and drug discovery and development. Regenerative medicine, which holds the larger share in the stem cells market, covers major disciplines such as orthopedics, hematology, wound care, diabetes, incontinence, neurology, oncology, cardiovascular and myocardial infarction, spinal cord injuries, and liver disorders.

Geographically, the global stem cells market is divided into Europe, Asia Pacific, North America, and Rest of the World. North America dominates the overall market, followed by Europe owing to increased prevalence of neurological and cardiac disorders, state initiatives and provision of grants from several organizations, development of innovative therapies, strong research activities, and effective marketing solutions. The Asia Pacific stem cells market is anticipated to witness impressive growth over the next two years thanks to rapidly growing contract research outsourcing and booming medical tourism.

Get a Sample for this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

The leading companies profiled in the stem cells market report are Osiris Therapeutics, Advanced Cell Technology, Cellartis AB, Bioheart, Cellular Engineering Technologies, Biotime Inc., Cytori Therapeutics Inc., Angel Biotechnology, Stemcelltechnologies Inc., California Stem Cell Inc., Brainstorm Cell Therapeutics, and Celgene Corporation Inc. These players are analyzed based on aspects such as company and financial overview, product portfolio, business strategies, and recent developments.

North America Leads Global Stem Cells Market, Asia Pacific to Register Fastest Growth

Regionally, the global stem cells market is segmented into Europe, Asia Pacific, North America, and Rest of the World. Of these regions, North America led the global stem cells market in 2011, holding a majority share in the global market. The region was followed by Europe, with a share of over 25% of global stem cells market the same year. High prevalence of neurological and cardiac diseases in the U.S, which, according to the Centers for Disease Control and Prevention, causes more than 50% of the total deaths in the country every year, is a significant factor contributing to the growth of the stem cells market in North America.

In the next couple of years, the stem cells market in Asia Pacific is expected to register a double-digit CAGR. The rapidly growing sector of medical tourism and increase in contract research outsourcing to the region are the factors likely to boost the stem cells market in Asia Pacific.

Mice Model Market expected to reach USD 1.75 Billion in 2023

Mice models have long been the backbone of fundamental and applied research in life sciences and continues to grow at a rapid rate. The mice model market has transformed since 2001, the year rodent genome was mapped. Mice models have a wide array of applications such as basic research, developing new therapeutic strategies for the treatment of human diseases, drug discovery and development research (such as target characterization, drug screening, and toxicity and safety evaluation), and preclinical studies of drug efficacy. Hundreds of mice models have been developed to study diseases such as cancer, Huntington’s, Parkinson’s, Duchenne and Becker muscular dystrophy, and amyotrophic lateral sclerosis (ALS). In the last 25 years, around 80% of discoveries in the biomedical research has been linked to research on mice.

The global mice model market was valued at USD 1,008.1 million in 2014 and is projected to reach USD 1,749.3 million in 2023, expanding at a CAGR of 6.4% from 2015 to 2023. Major factor boosting the growth of the market is the growing application of mice models not only in the field of basic research, but also in applied field of drug development and discovery. Development of mice models of human diseases has progressed rapidly in the past few years. Mice model has become indispensable in the evaluation of established and experimental treatment strategies, especially in cancer, cardiovascular diseases, metabolic anomalies, and neurological disorders. Mice model applications in drug discovery include development of new therapeutic strategies for the treatment of human diseases, target identification and validation, drug screening and lead optimization, and toxicity and safety screening. Furthermore, advancements in genetic engineering assisting in evaluating drug mechanism of action and its responses are expected to impact the growth of the drug discovery market. On the other hand, factors such as stringent regulatory framework that require precise control on use of animals in laboratories, rising concern on animal cruelty, and ethical concerns over the use of animals could negatively impact market growth.

The mice model market has been segmented into three major categories: model type, specialty, and services. Based on model type, inbred was the largest segment of the global mice model market in 2014 due to advantages such as cost effectiveness and data reproducibility. Metabolic & regulatory diseases was the largest specialty segment of the mice model market in terms of revenue in 2014. The segment accounted for 29.6% share of the market in 2014. The mice model services market is anticipated to expand at a CAGR of 7.3% from 2015 to 2023. The cryopreservation and cryorecovery services segment would expand at the highest growth rate during the forecast period as it requires less investment to maintain mice strain for a longer time.

Downlaod Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2085

Based on geography, the mice model market has been segmented into North America, Europe, Asia Pacific, Latin America, MENA, and Rest of the World (RoW). North America was the largest market for mice model in 2014. Ongoing robust research activities for the development of drugs and biologics and presence of major pharmaceutical and biotechnology companies in the region are some of the factors responsible for the dominance of the region. Europe held the second largest share of the global mice model market in terms of revenue in 2014. Asia Pacific is expected to be the fastest growing market for mice model during the forecast period from 2015 to 2023. This high growth is primarily due to improving economic condition in countries such as India and China, and increasing number of academic and research, and contract research organizations in Asia Pacific. Japan, China, Australia, and India are the major markets in Asia Pacific that offer immense opportunities to companies in the mice model market. Continuous increase in biomedical research expenditure in China and India are expected to play a key role in fueling the growth in these markets. The market in MENA, Rest of the World (RoW) and Latin America would also grow significantly due to increasing public and private investment in biomedical researches. In addition, factors such as improving health care infrastructure, rising awareness, and flexible regulatory requirements in the region are driving the mice model market.

Key players operating in the global mice model market include Charles River Laboratories, Crescendo Biologics Limited, Deltagen, Inc., genOway S.A., Harlan Laboratories, Inc., ImmunoGenes AG, Taconic Biosciences, Inc., Lexicon Pharmaceuticals, SAGE Labs, The Jackson Laboratory, and TransGenic, Inc.

Bioterrorism Detection Market Offering High-growth Opportunities for Market Players

A new report by Transparency Market Research (TMR), titled “Bioterrorism Detection Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,” provides a comprehensive study of this market taking its present as well as past performance into consideration.

Bioterrorism can be defined as the intentional propagation of biological agents such as viruses, bacteria, or toxins to spread terror in a specified place. The rising number of such incidences is causing immense harm to nature as well as humans. To avoid such situations, early detection of bioterrorism has emerged as the need of the hour.

The research study offers a comprehensive overview of the global market for bioterrorism detection and provides detailed information of the market segmentations. It also discusses the current as well as the imminent trends and the growth rate of this market and provides an insight into its future prospects.

The research report analyzes the worldwide bioterrorism detection market on the basis of it regional spread and the type of biological agents and their mode of delivery. As per the study, the global market is spread across North America, Asia Pacific, Europe, and the Rest of the World.

Based on the type of biological agents, the report segments the market into three categories. The first category consists of agents such as tularemia, anthrax, bubonic plague, smallpox viruses, hemorrhagic fever viruses, and botulinum toxins. These agents pose a high threat to the safety and security of human beings and animals.

The second category comprises toxins such as glanders, typhus, Q fever, and viral encephalitis. These toxins carry a moderate threat to the society and are less harmful than other agents. The third category includes emerging toxins that are specially developed for mass destruction, such as HIV/AIDS, Hantavirus, SARS, Nipah virus, and H1N1 virus. These viruses can be highly fatal and can cause major damage to human health.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1531

These biological agents are released into the environment by food contamination, water contamination, aerosol dissemination, insect vectors, and various other modes of delivery, notes the market study.

The research report also analyzes the global market for bioterrorism detection on the basis of the prevalent competitive landscape. Analysts have reviewed the company profiles of major participants to determine the current hierarchy of this market. According to it, PharmAthene Inc., Human Genome Sciences, Evogen Inc., ICX Technologies Inc., and Acambis Plc. are the leading players functioning in this market, states the research study.

The report attempts to present a clear picture of the global bioterrorism detection market to assist market participants in making important strategies for business expansion.